Measuring the ankle brachial index
may identify stroke survivors at risk of subsequent events
Measuring circulation in the ankle using a device similar
to a blood pressure cuff can help identify asymptomatic peripheral artery disease
(PAD) in stroke and transient ischemic attack (TIA) survivors, a group at much
higher risk of subsequent cerebrovascular events, according to a study in Stroke:
Journal of the American Heart Association.
The ankle brachial index (ABI) compares blood flow in
the ankle and the arm to detect poor circulation caused by fatty plaque buildup
in the lower body. Researchers used it to screen 102 stroke and TIA survivors.
The investigators found that 26 percent of the survivors had asymptomatic PAD,
and they had three times more subsequent cardiovascular events - stroke, heart
attacks or death - in the following two years compared to those without PAD. Fifty
percent with asymptomatic PAD suffered subsequent events, compared with 16 percent
of those without the disease. In addition, PAD was significantly associated with
future vascular events, especially strokes.
This is one of the first studies to find an independent
positive association between asymptomatic PAD and cardiovascular events among
stroke and TIA patients, according to the researchers.
PAD occurs when arteries in the extremities become obstructed
by plaque. Leg pain, cramping, weakness and limping during physical exertion are
the primary symptom, yet surveys show that up to one-third of patients never tell
their physician about symptoms, and fewer than half of general physicians routinely
ask.
"ABI measurement may be appropriate for screening stroke/TIA
patients who may be at high risk for vascular events," said lead researcher Souvik
Sen, M.D., M.P.H., director of the Stroke Center at the University of North Carolina,
Chapel Hill. "The test is easily performed in less than 15 minutes at the physician's
office or at bed-side in hospitalized patients."
PAD management guidelines developed by the American Heart
Association and the American College of Cardiology recommend screening all high-risk
patients.
The study was funded by BMS/Sanofi Pharmaceuticals.
|